Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Medullary Breast Carcinoma
93%
National Cancer Database
93%
Chemotherapy
50%
Overall Survival
50%
Bone Metastasis
46%
Simvastatin
46%
Brain Metastases
46%
Erlotinib
46%
Patients with Colorectal Cancer
46%
Pharmacologic
46%
Rhabdomyolysis
46%
Atypical Medullary Carcinoma
46%
General Community
46%
T2N0M0
46%
Tolerability
46%
B-cell Malignancies
46%
Center Experience
46%
Prognostic Factors
46%
Prognostic Survival
46%
Ibrutinib
46%
Bruton's Tyrosine Kinase Inhibitors (BTKi)
46%
Adverse Effects
28%
Metastasis
26%
Statins
23%
Toxicity Characteristics
23%
Metastatic Colorectal Cancer (mCRC)
19%
Tumor
19%
Without Chemotherapy
15%
Comorbidity
15%
Oxaliplatin
13%
Irinotecan
13%
Lymphocytosis
12%
Drug Interactions
11%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
11%
Locally Advanced
11%
Serum Levels
11%
Blood Cholesterol
11%
CYP3A4 Substrates
11%
Metastatic Non-small Cell Lung Cancer
11%
Liver
11%
Line of Therapy
11%
Tumor Size
11%
Immunoglobulin Levels
8%
IgG Levels
8%
Overall Response Rate
8%
IgA Level
8%
Drug Initiation
8%
Better Prognosis
7%
Multivariable
7%
Breast Cancer Patients
7%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
93%
Side Effect
50%
Neoplasm
46%
Bruton Tyrosine Kinase Inhibitor
46%
Monoclonal Antibody
46%
Simvastatin
46%
Tolerability
46%
Rhabdomyolysis
46%
Ibrutinib
46%
Erlotinib
46%
Vasculotropin
46%
Brain Metastasis
46%
Bone Metastasis
46%
Adverse Event
32%
Statin (Protein)
23%
Epidermal Growth Factor
23%
Epidermal Growth Factor Receptor
23%
Metastatic Colorectal Cancer
19%
Irinotecan
13%
Oxaliplatin
13%
Lymphocytosis
12%
Drug Interaction
11%
Non Small Cell Lung Cancer
11%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
CYP3A4
11%
Enzymes
11%
Cholesterol
11%
Atrial Fibrillation
8%
Immunoglobulin A
8%
Immunoglobulin
8%
Malignant Neoplasm
6%
Fox
6%
Lung Metastasis
6%
Primary Tumor
6%
Systemic Treatment
6%
Colon Carcinoma
6%
Medicine and Dentistry
Malignant Neoplasm
100%
Base
93%
Chemotherapy
53%
Medullary Carcinoma
46%
Prognostic Factor
46%
Breast Carcinoma
46%
Breast Cancer
46%
Colorectal Carcinoma
46%
Brain Metastasis
46%
Bone Metastasis
46%
Overall Survival
41%
Neoplasm
25%
Metastatic Colorectal Cancer
19%
Metastatic Carcinoma
19%
Ductal Carcinoma
13%
Irinotecan
13%
Oxaliplatin
13%
Tumor
12%
Comorbidity
11%
Lymph Node
6%
Survival Rate
6%
Estrogen Receptor
6%
Hormone Therapy
6%
Quadrantectomy
6%
Progesterone Receptor
6%
Therapeutic Agent
6%
Clinician
6%
Medical Record
6%
Patient Population
6%
Treatment Option
6%
Colon Carcinoma
6%
Primary Tumor
6%
Lung Metastasis
6%
Systemic Therapy
6%
Breast Cancer Chemotherapy
5%
Rare Tumor
5%
Distant Metastasis
5%
Proportional Hazards Model
5%
Adjuvant Chemotherapy
5%
Hazard Ratio
5%
Propensity Score Matching
5%
Radiation Therapy
5%
Diseases
5%